Hologic Announces Rule 10b5-1 Trading Plan

BEDFORD, Mass., Jan. 24, 2006 /PRNewswire-FirstCall/ -- Hologic, Inc. (NASDAQ: HOLX), a leading provider of state-of-the-art diagnostic and digital imaging systems directed towards women's health, today announced that an executive of the Company has a Rule 10b5-1 trading plan which will commence in February, 2006. This plan was adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934 and the Company's insider trading policy.

Glenn P. Muir, Executive Vice President and Chief Financial Officer, adopted a Rule 10b5-1 trading plan on August 4, 2005, while not in possession of any material nonpublic information. Under the plan, Mr. Muir will exercise stock options for 10,000 shares beginning on February 1, 2006 and continuing once each month for the remainder of 2006. A total of 110,000 shares are expected to be acquired upon exercise and sold for his account. The 10b5-1 trading plan is designed to enable Mr. Muir to diversify a portion of his Hologic equity interests in an orderly manner.

Rule 10b5-1 allows officers and directors to adopt written plans to sell shares under pre-arranged terms when they do not have material nonpublic information. The rule allows officers and directors adopting such plans to sell shares over a specified amount of time, at specific prices in the future, even if subsequent material and non-public information becomes available to them. Using these plans, officers and directors can gradually diversify their investment portfolios, can spread stock trades out over an extended period of time to reduce any significant market impact and can avoid concerns about whether they had material nonpublic information when they sold their stock. Sales of stock by Messr. Muir, pursuant to the terms of the plans, will be disclosed publicly through Form 144 and Form 4 filings with the Securities and Exchange Commission.

About Hologic Inc.

Hologic Inc. is a leading developer, manufacturer and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography and breast biopsy, direct-to- digital X-ray for general radiography applications and mini C-arm imaging for orthopedic applications.

  Frances Crecco
  Director, Investor Relations
  Hologic, Inc.
  (781) 999-7377

SOURCE: Hologic, Inc.

CONTACT: Frances Crecco, Director, Investor Relations of Hologic, Inc.,

Web site: